Because of the new California law, PBMs who do business in the state must now disclose to payers the amount they actually pay ...

The presentation places the EMERALD trial within the broader treatment context of metastatic ER+/HER2– disease. As resistance ...

An expert discusses how chronic kidney disease (CKD), often underdiagnosed and poorly recognized, is intricately linked with cardiovascular and metabolic conditions, emphasizing the urgent need for ...

In a single-center retrospective observational study at the Bari Polyclinic, researchers analyzed 50 adults with non-segmental vitiligo affecting 0.5 to 10% of their body surface area, including the ...

A new report released by the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) examines the global and ...

The FDA has accepted for review Chiesi’s New Drug Application (NDA) for their investigational maintenance treatment for ...

The concept of a cure in oncology, particularly for stage II and III colon cancer (CC), has historically suffered from ...

An expert discusses how treatment decisions must balance short-term burden with long-term benefits while avoiding ...

Panelists discuss how guselkumab demonstrated a very reassuring safety profile with no new safety signals or unexpected ...

Biomarkers are pivotal for confirming diagnoses, predicting disease progression, and tailoring therapeutic modalities. Recent ...

New diagnostics, including lab tests and imaging, are revolutionizing medicine and creating exciting opportunities for ...

An expert discusses how nonstatin therapies serve as essential tools when patients can’t tolerate statins or need additional ...